Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 829-myeloproliferative-disorders-or-poorly-differentiated-neoplasms-with-other-procedures-with-cc-mcc
    Ask Trek AI about this page

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    DRG 829 covers inpatient stays for patients with myeloproliferative disorders or poorly differentiated neoplasms undergoing other procedures with a Complication or Comorbidity or Major Complication or Comorbidity, impacting case complexity. This Diagnosis-Related Group matters for inpatient reimbursement because diagnosis severity, documented complications or comorbidities, and coded procedures affect Centers for Medicare & Medicaid Services payment and resource allocation.

    Customize your policy alerts

    Sign up for drg 829 policy alerts

    Get alerted when payer policies referencing 829 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 829 Overview

    DRG 829 includes inpatient stays for patients with myeloproliferative disorders or poorly differentiated neoplasms who undergo other procedures and have either a Complication or Comorbidity or a Major Complication or Comorbidity. Clinical scope covers hematologic malignancies and aggressive neoplasms requiring procedures such as bone marrow interventions, central venous access, or other operative/supportive procedures. This Diagnosis-Related Group matters for Centers for Medicare & Medicaid Services payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity and performed procedures influences the relative weight and reimbursement for the hospitalization. Accurate coding of diagnosis severity and procedures is essential to align payment with resource use.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials testing novel perioperative or inpatient procedural approaches for patients with myeloproliferative disorders or poorly differentiated hematologic neoplasms undergoing other procedures: these studies focus on optimizing timing, blood product management, anticoagulation reversal, and infection prophylaxis in hospitalized patients who require invasive procedures. The population includes adults with myelofibrosis, polycythemia vera, essential thrombocythemia, or high-grade/poorly differentiated hematologic malignancies who present for central line placement, biopsy, or minor surgical procedures with comorbidities classified as CC/MCC. Results are relevant to providers and payers because procedural complications, transfusion needs, and length of stay drive resource utilization and reimbursement under this DRG.
    • Comparative effectiveness studies of inpatient management strategies for acute complications (thrombosis, bleeding, leukostasis, or cytopenia-related infections) in the CC/MCC cohort: these trials compare different diagnostic algorithms, anticoagulation or transfusion thresholds, and supportive care pathways in hospitalized patients with myeloproliferative disorders or poorly differentiated neoplasms. Eligible patients are those admitted with acute hematologic complications requiring urgent intervention, often with significant comorbidity burden; the objective is to identify approaches that reduce ICU transfers, procedure rates, and readmissions. Payors and hospital systems benefit from evidence identifying care processes that safely shorten length of stay and lower costs while maintaining quality metrics captured in DRG-based reimbursement.
    • Post-discharge outcomes and care-transition research evaluating readmission prevention, outpatient monitoring, and rehabilitation needs after inpatient procedures in this population: these observational or intervention studies follow patients discharged after hospitalization with other procedures and CC/MCC to measure 30- and 90-day readmissions, complication rates, and outpatient resource use. The cohort comprises patients with myeloproliferative disorders or poorly differentiated neoplasms who had inpatient procedures and significant comorbidities, with attention to social determinants affecting follow-up adherence. Findings inform bundled-payment planning, discharge planning protocols, and payer strategies to reduce costly readmissions and downstream utilization associated with this DRG.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.